Welcome to our dedicated page for SenesTech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
SenesTech, Inc. reported that an account managed by Glenbrook Capital Management made a series of open-market purchases of its common stock. Between June 24 and June 29, 2026, the account bought a total of 25,416 shares at prices around $1.52–$1.56 per share. After these transactions, the account held 987,824 shares of SenesTech common stock indirectly. Glenbrook Capital Management is investment manager to the account and disclaims beneficial ownership of these securities except to the extent of its pecuniary interest.
SenesTech, Inc. reported that Glenbrook Capital Management, as investment manager for an account it oversees, made two open-market purchases of SenesTech common stock. The account bought 3,264 shares at $1.6139 per share on June 17, 2026 and 5,000 shares at $1.6591 per share on June 22, 2026, for a total of 8,264 shares purchased. Following these transactions, the account held 962,408 shares of SenesTech common stock indirectly. Glenbrook Capital Management disclaims beneficial ownership of these securities for Section 16 purposes except to the extent of any pecuniary interest.
SenesTech, Inc. director Joshua Matthew Moss received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $1.65 per share, expire on June 15, 2036, and vest in 12 equal monthly installments over one year. Following this award, Moss holds derivative options on 100,000 shares directly.
SenesTech, Inc. director Phillip Nicholas Grandinetti III received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $1.65 per share, become exercisable over one year in 12 equal monthly installments, and expire on June 15, 2036. Following this award, he holds stock options for 100,000 shares directly.
SenesTech, Inc. director Jacob Steven Leach received a stock option grant covering 100,000 shares of common stock. The option has an exercise price of $1.65 per share, was granted on June 15, 2026, and expires on June 15, 2036.
The award vests monthly over one year in 12 equal installments, starting after the grant date. Following this grant, Leach holds derivative rights to acquire 100,000 shares through this option, reflecting a compensation-related equity incentive rather than an open-market purchase or sale.
SenesTech, Inc. director Matthew K. Szot received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $1.6500 per share, were granted at no cost, and vest in 12 equal monthly installments over one year. The options expire on June 15, 2036, and following this grant Szot holds 100,000 options directly as compensation rather than through any open-market purchase.
SenesTech, Inc. reported that its CFO and Treasurer, Thomas C. Chesterman, received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $1.65 per share and expire on June 15, 2036.
The award vests in 12 equal quarterly installments over three years, giving the executive the right to buy up to 75,000 shares of SenesTech common stock if the options are exercised after vesting.
SenesTech, Inc. director Graham Lynn Yako received a grant of stock options as part of his compensation. He was awarded 100,000 Stock Options (right to buy), each giving the right to purchase one share of common stock at an exercise price of $1.65 per share.
The options relate to 100,000 shares of common stock and expire on June 15, 2036. Following this grant, Yako holds 100,000 options directly. A footnote states the award vests monthly over one year in 12 equal installments, indicating a time-based vesting schedule rather than an immediate, fully vested grant.
SenesTech, Inc. director Jamie Bechtel Morrison received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $1.6500 per share and expire on June 15, 2036. According to a footnote, the award vests monthly over one year in 12 equal installments, providing compensation that aligns the director’s incentives with long-term shareholder value. Following this grant, the filing shows 100,000 derivative securities held directly, and no sales or exercises were reported in this filing.
SenesTech, Inc. disclosed that Chief Executive Officer Michael Edell received a grant of stock options covering 263,288 shares of common stock. The options have an exercise price of $1.47 per share and expire on May 6, 2036. According to the vesting terms, one-twelfth of the options will vest on the last day of each calendar quarter starting on June 30, 2026, subject to continuous service, with full vesting expected by March 31, 2029. The filing notes that exercisability of any portion exceeding the shares available under the stockholder-approved plan reserve will require additional stockholder approval.